

Published in final edited form as:

*Occup Environ Med.* 2015 June ; 72(6): 435–441. doi:10.1136/oemed-2014-102654.

## SOFT TISSUE SARCOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA IN WORKERS EXPOSED TO PHENOXY HERBICIDES: EXTENDED FOLLOW-UP OF A UK COHORT

David Coggon, Georgia Ntani, E Clare Harris, Nimeshi Jayakody, and Keith T Palmer  
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

### Abstract

**Objectives**—To provide further information on the possible carcinogenicity of phenoxy herbicides, and in particular their relationship to soft tissue sarcoma (STS), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).

**Methods**—We extended follow-up to December 2012 for 8,036 men employed at five factories in the UK which had manufactured phenoxy herbicides, or in a contract spraying business. Mortality was compared with that for England and Wales by the person-years method. Nested case-control analyses compared men with incident or fatal STS (n=15) or NHL/CLL (n=74) and matched controls (up to 10 per case).

**Results**—4,093 men had died, including 2,303 since the last follow-up. Mortality from all causes and all cancers was close to expectation, but an excess of deaths from NHL was observed among men who had worked for ≥ 1 year in jobs with more than background exposure to phenoxy herbicides (19 deaths, standardised mortality ratio 1.85, 95% confidence interval (CI) 1.12–2.89). Four deaths from STS occurred among men potentially exposed above background (3.3 expected). In the nested case-control analyses, there were no significantly elevated risks or consistent trends across categories of potential exposure, for either STS or NHL/CLL. The highest odds ratio (for STS in men who had worked for ≥ 1 year in potentially exposed jobs) was only 1.30 (95% CI 0.30–5.62).

**Conclusions**—Our findings are consistent with the current balance of epidemiological evidence. If phenoxy herbicides pose a hazard of either STS or NHL then any absolute increase in risk is likely to be small.

### Keywords

Phenoxy; MCPA; 2,4-D; soft tissue sarcoma; non-Hodgkin lymphoma; chronic lymphocytic leukaemia; cohort; mortality; incidence

## Introduction

The phenoxy herbicides are a class of selective weed-killers, which since their first commercial production in the 1940s have been widely used in agriculture, forestry, parks and gardens. They include, among others, the compounds 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), 2,4-dichlorophenoxyacetic acid (2,4-D) and 2-methyl-4-chlorophenoxyacetic acid (MCPA). 2,4,5-T is liable to contamination during manufacture by 2,3,7,8-tetrachlorodibenzodioxin (TCDD) [1] which is an established human carcinogen [2], and products containing 2,4,5-T are no longer approved for use in the European Union or the USA. TCDD is not found in other phenoxy herbicides, although some of them may contain traces of other, less toxic, dioxin congeners [3].

Phenoxy acids and their salts and esters are not genotoxic, and have not been found to cause cancer when tested in laboratory animals [3-5]. However, early case-control studies in Sweden suggested associations with soft tissue sarcoma (STS) [6,7] and non-Hodgkin lymphoma (NHL) [8], with odds ratios for occupational use in excess of five. Since then, extensive epidemiological research has failed to confirm either hazard, and currently chlorophenoxy acids are classified by the International Agency for research on Cancer (IARC) only as possibly carcinogenic to humans (Group 2B) [9]. However, some studies have produced positive results, and recent systematic reviews have concluded that because of statistical uncertainties, it is not possible to rule out an increased risk of these cancers [10, 11]. In particular, the single most robust and informative investigation, which was a case-control analysis nested within a large international cohort study coordinated by IARC, found an odds ratio of 10.3 (95% confidence interval 1.2-91) for STS in workers exposed to any phenoxy herbicide [12].

The 36 sub-cohorts that contributed to the IARC study included employees at five factories in the UK which had manufactured phenoxy herbicides, together with a group of contract pesticide sprayers who had worked for one of the same companies [13,14]. The last published follow-up of these workers was as part of the IARC study [15], and covered a period up to 1990/91.

To provide further information on the possible carcinogenicity of phenoxy herbicides, and in particular their relationship to STS, NHL and chronic lymphocytic leukaemia (CLL) (which is now considered a form of NHL [16,17]), we extended follow-up of the six British sub-cohorts to December 2012.

## Methods

The definition of the cohort and potential exposures of cohort members are summarised in Table 1. All of the sub-cohorts were engaged in the manufacture, formulation or application of a range of phenoxy herbicides, as well as other products, although not all of the compounds listed in Table 1 were handled throughout the entire period during which subjects might have worked. Further information about this, and about the manufacturing processes, has been reported previously [13,14]. 2,4,5-T was produced at one factory (sub-

cohort A) during 1968-78, and at times was formulated at each of the other factories (subcohorts B-E). However, it was virtually never used by the sprayers (sub-cohort F).

At each company, cohort members were identified from personnel, wages or other plant records, and demographic information was abstracted together with job histories. The latter were then used to classify subjects according to the timing and duration of their potential exposure to phenoxy compounds. This classification was based on dates of starting and finishing relevant jobs. Because products were manufactured and formulated in campaigns, and sprayers applied other products as well as phenoxy herbicides, exposures would have been intermittent. The classification took into account that sprayers would not use phenoxy herbicides during the autumn and winter months, but beyond this, we did not have information on the dates of exposures within jobs. Thus, it was only possible to determine periods when an individual was liable to be exposed. Some jobs (e.g. clerical staff, sales workers and managers who did not normally enter production areas) were classed as having only background exposure. Most individuals who worked for longer than a year in other jobs would have experienced exposures substantially above background. In sub-cohorts E and F, we further distinguished between jobs with high potential for exposure (principally chemical process workers, certain laboratory occupations and spray operatives) and others in which average exposures over the long term were likely to be lower (e.g. maintenance staff, workers in chemical stores and transport). For a few men in sub-cohorts E and F, job title was available for only the most recent of several jobs that had been held at the company, and it was assumed that earlier jobs had similar exposure to the one that was recorded.

The cohort was traced through the Health and Social Care Information Centre (HSCIC – previously the National Health Service Central register) to the end of 2012, with supplementary information in a few cases from national insurance records. Information was obtained about all deaths and cancer registrations, and also about loss to follow-up from emigration or for other reasons. Underlying and contributing causes of death were coded to the ninth revision of the International Classification of Diseases (ICD 9) for deaths up to December 2000, and the tenth revision (ICD 10) for those that occurred subsequently. For subjects with registered cancers, we obtained information about the type of cancer and date of registration.

Statistical analysis was carried out with Stata (Version 13) software (StataCorp LP, College Station, Texas). The person-years method was used to compare the mortality of the cohort by underlying cause of death with that in the national population of England and Wales. The reference rates were for five-year age bands and five-year calendar periods (except for deaths during 2010-2012, for which rates during 2005-2012 were used). A worker was considered to be at risk from the later of: a) the date from which he met the criteria for entry to the cohort; and b) the date when he first entered the relevant exposure category. He then remained at risk until the earliest of: a) exit from the relevant exposure category; b) death; c) loss to follow-up for other reasons; or d) 31 December 2012. Men who could not be traced at the HSCIC or through the National Insurance Index were treated as lost to follow-up at their last known date of employment. Results were summarised as standardised mortality ratios (SMRs) with 95% confidence intervals (95% CIs).

In addition to the person-years analysis, we carried out a nested case-control study of STS and for the combination of NHL and CLL. For this, we identified cases not only from underlying causes of death, but also from cancer registrations (which included information about histology) and from contributing causes on death certificates. We then applied a prescribed algorithm to match each case with up to 10 controls from the same sub-cohort, who had the same year of birth to within two years, and were under follow-up at the time when the case was first recorded as having STS or NHL/CLL. Associations with duration of potential exposure to phenoxy herbicides (lagged by five years) were assessed by conditional logistic regression, and summarised by odds ratios (ORs). These analyses excluded a small number of subjects (22) whose date of first potential exposure for at least one year was unknown.

## Results

Table 1 shows the numbers of men who were included in the analysis by sub-cohort, and also the numbers who were classed as having potential for exposures above background. In total, the cohort comprised 8,036 subjects, including 54 who belonged to both of sub-cohorts E and F, and whose occupational histories from the two categories of employment were merged. Most men (6,168, 76.8%) had worked in jobs entailing greater than background exposure to phenoxy acids, including 2,653 (33.0%) with potential for such exposure over a year or longer. In sub-cohorts E and F, a total of 1,669 workers had been employed for at least a year in jobs with potential for high exposure.

Over the full period of study there were 4,093 deaths, including 2,303 since the last follow-up in 1990/91. One hundred and thirty six subjects could not be traced at HSCIC or through National Insurance records, and were followed only to their last known date of employment. A further 772 were lost to follow-up subsequently, including 297 because of emigration.

Table 2 summarises the mortality of the cohort from major categories of disease. In comparison with national rates, mortality was close to expectation for all causes, all cancers, and each of circulatory and respiratory disease, both in the cohort as a whole, and in the subset of workers with potential exposure to phenoxy acids above background (SMRs 0.94 to 1.02). However, there was a significant excess of deaths from injury and poisoning (187 deaths, SMR 1.26, 95%CI 1.08-1.45 overall; 141 deaths, SMR 1.26, 95%CI 1.06-1.49 in those with potential for more than background exposure), and from digestive diseases among men potentially exposed above background (120 deaths, SMR 1.20, 95%CI 1.00-1.44). Most of the deaths from injury and poisoning (103/187) occurred when workers were no longer employed at the participating companies, and they were largely in sub-cohort F. None of the deaths during employment was from accidental poisoning by pesticides.

Table 3 shows the mortality of cohort members from specific categories of cancer, overall and by duration of potential for exposure above background. There was an excess of deaths from NHL among men who had worked for a year or longer in exposed jobs (19 deaths, SMR 1.85, 95%CI 1.12-2.89), but no other significant associations were observed. There were four deaths from STS (3.3 expected) among men potentially exposed above

background, including three (1.5 expected) in those who had done such work for at least a year.

Supplementary Tables S1 to S6 show separate findings for each sub-cohort on mortality from major causes of death and from the more common cancers (>10 deaths observed or expected in the full cohort) among workers potentially exposed above background. Results are presented both for the entire follow-up period, and also for the period since the cohort was last analysed as part of the IARC collaborative study [15]. Three sub-cohorts (A, B and D) had significantly elevated total mortality (SMRs of 1.58, 1.47 and 1.28 respectively), which was driven mainly by excesses of deaths from respiratory and digestive disease, and in sub-cohort A, also from circulatory disease (136 deaths, SMR 1.80, 95%CI 1.51-2.13). In these three sub-cohorts mortality from lung cancer was also higher than expected (SMRs of 1.46, 1.66 and 1.76 based on 26, 8 and 27 deaths respectively). In contrast, patterns of mortality in sub-cohorts C, E and F were unremarkable.

In addition to the four deaths from STS that were included in the person-years analysis summarised in Table 3, we identified a further 11 cases from scrutiny of death certificates and cancer registrations, giving a total of 15 (Table 4), who were matched with 150 controls. Twenty nine cases of NHL and 12 of CLL were recorded as underlying causes of death, and a further 20 and 13 respectively were ascertained from contributing causes of death and cancer registrations (Supplementary Table S7). This gave a total of 74 cases of NHL/CLL, who were matched with 719 controls. Table 5 summarises the associations of STS and NHL/CLL with duration and level of potential for exposure above background. There were no significantly elevated risks or consistent trends across categories of potential exposure, for either group of cancers. The highest odds ratio (for soft tissue sarcoma in men who had worked for at least one year in jobs with potential exposure) was only 1.30 (95%CI 0.30-5.62).

## Discussion

Our extended follow-up added substantially to the information that was previously available for the six sub-cohorts studied, with an additional 2,303 deaths available for analysis. Comparison of mortality with that in the national population suggested a possible risk of NHL. However, that was not supported by a nested case-control analysis which included cases with non-fatal as well as fatal disease, and also men with CLL, which is now thought to be classified most appropriately with solid non-Hodgkin lymphomas [16,17]. Nor did we find an increased risk of STS, either in person-years or nested case-control analyses.

Apart from its size, a major strength of our study was the high exposures that are likely to have been incurred by many of the subjects in comparison with those studied in community-based case-control investigations. Furthermore, the assessment of exposure did not rely on subjects' personal recall, which is often liable to differential error in case-control studies, leading to spurious overestimation of risk. On the other hand, because the production and application of phenoxy herbicides was intermittent, the individual exposures of our cohort members could not be ascribed with certainty. We think it unlikely that many men classed as having only background exposure would in fact have had higher exposures – for example,

because they were still employed at the time when the sub-cohorts were assembled and later moved to other jobs at the same companies (it was not practical to update occupational histories for such workers). However, it may be that some men classed as potentially exposed above background did not in fact experience such exposure, especially if they were only in relevant jobs for short periods. Any such error will have tended to bias risk estimates towards the null.

Another challenge was reliable and complete ascertainment of the cancers of main interest. Survival rates for STS and NHL are relatively high, meaning that cases will not necessarily be picked up from death certificates. Moreover, deaths from STS are often coded as cancers of the anatomical site at which they occur (along with more numerous carcinomas) rather than as STS specifically. These problems were addressed by ascertaining cases also from cancer registrations (which include a separate histology code) and from contributing causes on death certificates. Because in the past the completeness of cancer registration in England and Wales varied by region, there were no suitable comparator rates for a person-years analysis of cancer incidence. Instead, therefore, we carried out nested case-control analyses in which controls were matched to cases by sub-cohort as well as approximately by year of birth.

The nested case-control study of STS included 15 cases and 150 controls, and as such was the largest such analysis to date. A previous case-control study nested within the IARC international cohort study was based on 11 cases of STS and 55 controls [12]. That study found an OR of 10.32 (95% CI 1.18-90.56) for exposure to any phenoxy herbicide, with only one of 11 cases classed as unexposed. In contrast, risk estimates in our study were much lower (ORs 1.30, 95% CI 0.30-5.62, for potential exposure over 1 year; and 0.95, 95% CI 0.19-4.88, for potential high exposures in sub-cohorts E and F). While misclassification of exposures may have caused a little bias towards the null, these results suggest that any increase in risk for this rare group of tumours is at most small, and substantially less than was suggested by early case-control studies, which may have been prone to important recall bias [6,7].

While we did find a significant excess of deaths from NHL in our person-years analysis (SMR 1.85, 95% CI 1.12-2.89), we consider that greater weight should be given to the nested case-control analysis, which included non-fatal as well as fatal cases, and men with CLL as well as solid lymphomas. That analysis found no significant elevation of risk with exposure to phenoxy herbicides, the highest risk estimate (for those with potential for high exposure in sub-cohorts E and F) being 1.22 (95% CI 0.61-2.46). This is consistent with the findings of a recent systematic review, which examined results for NHL from 13 cohort and 20 case-control studies, and found little evidence of in support of a hazard [11].

Although our findings for STS and NHL gave little indication of a hazard, three of the subcohorts exhibited notably elevated mortality from all causes, respiratory disease, digestive disease, lung cancer, and in the case of sub-cohort A, also circulatory disease. The excess of circulatory disease in sub-cohort A was noted when the cohort was first analysed in 1991 [14]. At that time, a nested case-control analysis did not suggest an association with work in any specific department, and it was concluded that the elevated mortality might be

attributable to a combination of smoking and other non-occupational causes. A confounding effect of smoking (about which we did not have data) would be consistent with the increased mortality from respiratory disease and lung cancer, which was found also in sub-cohorts B and D. It seems unlikely that the excesses of these diseases were caused by phenoxy herbicides, since they did not extend to the other three sub-cohorts. Nor has a relationship to these diseases been suggested by other cohort studies of phenoxy herbicide workers. For example, in the IARC international cohort of workers exposed to phenoxy herbicides and chlorophenols, the SMRs for circulatory disease, respiratory disease and lung cancer in men were 0.91 (95% CI 0.87-0.95), 0.82 (95% CI 0.72-0.92) and 1.09 (95% CI 0.98-1.20) [15]. The factories at which sub-cohorts A, B and D worked were all located in relatively deprived industrial areas, whereas sub-cohorts C, E and F were based in more affluent places.

Overall, the results of our extended follow-up are consistent with the current balance of epidemiological evidence in not pointing clearly to a hazard of either STS or NHL. Given the rarity of these cancers, the findings suggest that if there is a hazard, then any absolute increase in risk is likely to be small.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgement

We thank the staff of the Health and Social Care Information Centre for their assistance with tracing of subjects, and Vanessa Cox who prepared the data file for analysis.

The study was supported by a grant from the Colt Foundation (CF/03/10).

## References

1. Saracci R, Kogevinas M, Bertazzi P-A, Bueno de Mesquita BH, Coggon D, Green LM, et al. Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. *Lancet*. 1991; 338:1027–32. [PubMed: 1681353]
2. International Agency for Research on Cancer. Chemical agents and related occupations. International Agency for Research on Cancer; Lyon: 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol 100F)
3. International Agency for Research on Cancer. Some halogenated hydrocarbons and pesticide exposures. IARC; Lyon: 1986. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 41
4. Ibrahim MA, Bond GG, Burke TA, Cole P, Dost FN, Enterline PE, et al. Weight of evidence on the human carcinogenicity of 2,4-D. *Environ Health Perspect*. 1991; 96:213–22. [PubMed: 1820267]
5. Bond GG, Rossbacher R. A review of potential human carcinogenicity of the chlorophenoxy herbicides MCPA, MCPP, and 2,4-DP. *Br J Indust Med*. 1993; 50:340–8.
6. Hardell L, Sandström A. Case-control study: soft tissue sarcomas and exposure to phenoxy acetic acids of chlorophenols. *Br J Cancer*. 1979; 39:711–17. [PubMed: 444410]
7. Eriksson M, Hardell L, Berg NO, Möller T, Axelson O. Soft-tissue sarcomas and exposure to chemical substances: a case-referent study. *Br J Indust Med*. 1981; 38:27–33.
8. Hardell L, Eriksson M, Lenner P, Lundgren E. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study. *Br J Cancer*. 1981; 43:169–76. [PubMed: 7470379]

9. International Agency for Research on Cancer. Agents Classified by the IARC Monographs. Volumes 1–109 <http://monographs.iarc.fr/ENG/Classification/ClassificationsAlphaOrder.pdf>.
10. von Stackelberg K. A systematic review of carcinogenic outcomes and potential mechanisms from exposure to 2,4-D and MCPA in the environment. *J Toxicol*. 2013 Article ID 371610.
11. Jayakody N, Harris EC, Coggon D. Phenoxy herbicides, soft tissue sarcoma and non-Hodgkin lymphoma: a systematic review of evidence from cohort and case-control studies. Submitted for publication.
12. Kogevinas M, Kauppinen T, Winkelmann R, Becher H, Bertazzi PA, Bueno de Mesquita HB, et al. Soft tissue sarcoma and non-Hodgkin's lymphoma in workers exposed to phenoxy herbicides, chlorophenols, and dioxins: two nested case-control studies. *Epidemiology*. 1995; 6:396–402. [PubMed: 7548348]
13. Coggon D, Pannett B, Winter PD, Acheson ED, Bonsall J. Mortality of workers exposed to 2 methyl-4 chlorophenoxyacetic acid. *Scand J Work Environ Health*. 1986; 12:448–54. [PubMed: 3787216]
14. Coggon D, Pannett B, Winter P. Mortality and incidence of cancer at four factories making phenoxy herbicides. *Br J Ind Med*. 1991; 48:173–8. [PubMed: 2015208]
15. Kogevinas M, Becher H, Benn T, Bertazzi PA, Boffetta P, Bueno-de-Mesquita HB, et al. Cancer mortality in workers exposed to phenoxy herbicides, chlorophenols, and dioxins. *Am J Epidemiol*. 1997; 145:1061–75. [PubMed: 9199536]
16. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond; evolving concepts and practical applications. *Blood*. 2011; 117:5019–32. [PubMed: 21300984]
17. National Cancer Institute. [accessed 21.10.14] Non-Hodgkin lymphoma. <http://www.cancer.gov/cancertopics/types/non-hodgkin>



### What this paper adds

- Previous studies have suggested an increased risk of soft tissue sarcoma and non-Hodgkin lymphoma in workers exposed to phenoxy herbicides, but evidence has been inconsistent and the existence of a hazard remains controversial
- In extended follow-up of a large British cohort of chemical manufacturers and pesticide sprayers, we found little indication that exposure to phenoxy herbicides increases the risk of either disease
- If phenoxy herbicides pose a hazard of either STS or NHL then any absolute increase in risk is likely to be small.

Table 1

## Definition of cohort and potential exposures

Sub-cohort	Activity	Phenoxy herbicides produced, formulated or applied <sup>a</sup>	Other chemicals produced, formulated or applied	Definition of cohort	No. of men	Number potentially exposed to phenoxy acids above background	
						Ever	For 1 year
A	Manufacture and formulation	2,4,5-T; 2,4-D; 2,4-DP; 2,4-DB; MCPA; MCPP; MCPB; PCPA; PAA	Picric acid; dinitro-o-butyl phenol; dinitro-o-cresol; simazine; aminotriazole; oxynils	All manual employees during April 1975-October 1985	1,146	934	462
B	Manufacture and formulation	2,4,5-T; 2,4-D; 2,4-DP; 2,4-DB; MCPA; MCPP; MCPB	Dithiocarbamates; organophosphorus compounds; carbamates; dinocap; toluidine compounds; urea herbicides; imidazole compounds; phthalimide compounds	All weekly paid employees during March 1969-November 1985	272	272	86
C	Manufacture and formulation	2,4,5-T; 2,4-D; MCPB; PBA	Aminophylline; metronidazole; sulphonamides; oxynils; dinocap; asulam; sodamide; diflufenican	All process workers on phenoxy plant during January 1963-December 1984; all formulators and packers during January 1982-December 1984; All maintenance workers during July 1967-December 1984	345	345	185
D	Manufacture and formulation	2,4,5-T; 2,4-D; 2,4-DP; MCPA; MCPP	Metallic soaps; plasticiser esters; naphthenic acid; alkyl phenols; phthalate esters; 2,4,6-trichlorophenol	All weekly paid employees during April 1969-December 1985	520	511	251
E	Manufacture and formulation	MCPA; 2,4,5-T; and others	Copper oxychloride; dinitro orthocresol; organophosphorus compounds; chlorotriazine herbicides	All men employed during January 1947-December 1975	2,738	1,544	848
F	Contract spraying	MCPA; others but virtually never 2,4,5-T	Copper oxychloride; dinitro orthocresol; organophosphorus compounds; chlorotriazine herbicides	All men employed during January 1947-December 1975	3,015	2,562	821

<sup>a</sup> 2,4,5-T = 2,4,5-trichlorophenoxyacetic acid; 2,4-D = 2,4-dichlorophenoxyacetic acid; 2,4-DP = 2,4-dichlorophenoxypropionic acid; 2,4-DB = 2,4-dichlorophenoxybutyric acid; MCPA = 2-methyl-4-chlorophenoxyacetic acid; MCPP = 2-methyl-4-chlorophenoxypropionic acid; MCPB = 2-methyl-4-chlorophenoxybutyric acid; PCPA = parachlorophenoxyacetic acid; PAA = phenoxyacetic acid; PBA = phenoxybutyric acid

<sup>b</sup> Includes 24 men who subsequently worked also in cohort F

<sup>c</sup> Includes 30 men who subsequently worked also in cohort E

Table 2

Mortality of cohort from major disease categories, 1947-2012

Cause of death	ICD Codes		All workers				Workers potentially exposed to phenoxy acids above background			
	ICD 9	ICD 10	Deaths observed	Deaths expected	SMR	(95% CI)	Deaths observed	Deaths expected	SMR	(95% CI)
All cancers	140-208	C00-C97	1,205	1,213.8	0.99	0.94-1.05	900	880.7	1.02	0.96-1.09
Circulatory disease	390-459	I00-I99	1,737	1,793.0	0.97	0.92-1.02	1,227	1,263.2	0.97	0.92-1.03
Respiratory disease	460-519	J00-J99	454	484.7	0.94	0.85-1.03	323	335.7	0.96	0.86-1.07
Digestive diseases	008-009, 520-579	K00-K93	156	136.4	1.14	0.97-1.34	120	99.7	1.20	1.00-1.44
Injury and poisoning	800-999	U509, V01-Y89	187	148.6	1.26	1.08-1.45	141	111.5	1.26	1.06-1.49
All Causes	001-999	A00-R99, U5009, V01-Y89	4,093	4,084.0	1.00	0.97-1.03	2,974	2,911.7	1.02	0.99-1.06

Table 3

Mortality of cohort from specific cancers, 1947–2012

Cancer	ICD Codes		All workers					Workers potentially exposed to phenoxy acids above background					Workers potentially exposed to phenoxy acids above background for 1 year <sup>c</sup>					
	ICD 9	ICD 10	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI
Lip	140	C00	0	0.3	0.00	0.00-11.53	0	0.2	0.00	0.00-17.45	0	0.1	0.00	0.00-35.84	0	0.1	0.00	0.00-35.84
Tongue	141	C01-C02	8	4.2	1.93	0.83-3.80	5	3.1	1.63	0.53-3.80	3	1.4	2.16	0.45-6.32	3	1.4	2.16	0.45-6.32
Mouth <sup>d</sup>	143-145	C03-C06	2	3.8	0.53	0.06-1.90	1	2.8	0.36	0.01-1.99	0	1.3	0.00	0.00-2.89	0	1.3	0.00	0.00-2.89
Pharynx <sup>d</sup>	146-149.1	C09-C14.2	4	8.2	0.49	0.13-1.25	4	6.1	0.66	0.18-1.68	0	2.7	0.00	0.00-1.34	0	2.7	0.00	0.00-1.34
Oesophagus	150	C15	55	55.8	0.99	0.74-1.28	46	41.6	1.11	0.81-1.48	17	19.0	0.89	0.52-1.43	17	19.0	0.89	0.52-1.43
Stomach	151	C16	66	84.3	0.78	0.61-1.00	43	58.8	0.73	0.53-0.99	21	28.0	0.75	0.46-1.15	21	28.0	0.75	0.46-1.15
Small intestine <sup>d</sup>	152	C17	4	2.4	1.67	0.46-4.28	4	1.8	2.26	0.62-5.80	2	0.8	2.48	0.30-8.96	2	0.8	2.48	0.30-8.96
Large intestine	153	C18	77	79.1	0.97	0.77-1.22	50	57.3	0.87	0.65-1.15	23	26.8	0.86	0.54-1.29	23	26.8	0.86	0.54-1.29
Rectum	154	C19-C21	39	51.5	0.76	0.54-1.04	31	37.1	0.84	0.57-1.19	14	17.3	0.81	0.44-1.36	14	17.3	0.81	0.44-1.36
Liver <sup>b</sup>	155.0-155.1	C22	20	16.2	1.24	0.76-1.91	14	12.3	1.14	0.62-1.91	4	5.5	0.72	0.20-1.85	4	5.5	0.72	0.20-1.85
Gall bladder <sup>b</sup>	156	C23-C24	2	4.7	0.43	0.05-1.55	1	3.3	0.30	0.01-1.68	0	1.6	0.00	0.00-2.35	0	1.6	0.00	0.00-2.35
Pancreas	157	C25	54	52.0	1.04	0.78-1.35	39	38.0	1.03	0.73-1.40	13	17.6	0.74	0.39-1.26	13	17.6	0.74	0.39-1.26
Nose and nasal sinuses	160	C30-C31	3	1.7	1.80	0.37-5.26	3	1.2	2.50	0.52-7.31	0	0.6	0.00	0.00-6.66	0	0.6	0.00	0.00-6.66
Larynx	161	C32	7	10.7	0.66	0.26-1.35	7	7.7	0.91	0.36-1.87	3	3.6	0.84	0.17-2.44	3	3.6	0.84	0.17-2.44
Lung	162	C33-C34	392	388.7	1.01	0.91-1.11	298	278.7	1.07	0.95-1.20	138	131.4	1.05	0.88-1.24	138	131.4	1.05	0.88-1.24
Bone	170	C40-C41	4	2.5	1.60	0.44-4.09	3	1.8	1.67	0.35-4.89	1	0.8	1.27	0.03-7.07	1	0.8	1.27	0.03-7.07
Soft tissue sarcoma <sup>d</sup>	171	C46, C47, C49	4	4.3	0.92	0.25-2.36	4	3.3	1.22	0.33-3.13	3	1.5	2.05	0.42-5.98	3	1.5	2.05	0.42-5.98
Melanoma <sup>d</sup>	172	C43	7	10.7	0.66	0.26-1.35	6	8.2	0.73	0.27-1.59	2	3.6	0.55	0.07-2.00	2	3.6	0.55	0.07-2.00
Other skin <sup>d</sup>	173	C44	4	3.5	1.15	0.31-2.93	2	2.5	0.81	0.10-2.91	0	1.2	0.00	0.00-3.15	0	1.2	0.00	0.00-3.15
Prostate	185	C61	120	108.8	1.10	0.91-1.32	89	77.9	1.14	0.92-1.41	43	37.3	1.15	0.83-1.55	43	37.3	1.15	0.83-1.55
Testis <sup>d</sup>	186	C62	5	2.5	2.00	0.65-4.67	4	1.9	2.10	0.57-5.37	3	0.7	4.03	0.83-11.78	3	0.7	4.03	0.83-11.78
Other genital <sup>d</sup>	187	C63	2	1.2	1.60	0.19-5.79	2	0.9	2.30	0.28-8.31	1	0.4	2.42	0.06-13.49	1	0.4	2.42	0.06-13.49
Bladder <sup>d</sup>	188	C65-C68	44	48.0	0.92	0.67-1.23	30	34.3	0.87	0.59-1.25	16	16.3	0.98	0.56-1.59	16	16.3	0.98	0.56-1.59
Kidney <sup>d</sup>	189	C64	23	26.4	0.87	0.55-1.31	16	19.7	0.81	0.46-1.32	11	9.0	1.22	0.61-2.19	11	9.0	1.22	0.61-2.19

Cancer	ICD Codes		All workers					Workers potentially exposed to phenoxy acids above background					Workers potentially exposed to phenoxy acids above background for 1 year <sup>c</sup>					
	ICD 9	ICD 10	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI	Obs	Exp	SMR	95%CI
Brain and nervous system	191,192	C71-C72	33	28.7	1.15	0.79-1.62	25	21.8	1.15	0.74-1.70	10	9.6	1.04	0.50-1.92				
Thyroid	193	C73	3	1.9	1.56	0.32-4.57	3	1.4	2.15	0.44-6.28	2	0.6	3.11	0.38-11.22				
Hodgkin's disease	201	C81	3	5.7	0.53	0.11-1.55	3	4.2	0.72	0.15-2.11	3	1.8	1.71	0.35-4.99				
Non-Hodgkin lymphoma <sup>a</sup>	200,202.0, 202.1,202.8	C82-C85	29	30.2	0.96	0.64-1.38	26	22.6	1.15	0.75-1.68	19	10.3	1.85	1.12-2.89				
Multiple myeloma <sup>a</sup>	203.0	C90	18	17.3	1.04	0.62-1.64	15	12.8	1.18	0.66-1.94	6	5.9	1.01	0.37-2.20				
Leukaemia	204-208	C91-C95	40	31.6	1.27	0.91-1.73	30	23.2	1.29	0.87-1.84	11	10.6	1.04	0.52-1.86				
Myeloid leukaemia <sup>a</sup>	205	C92	22	18.1	1.21	0.76-1.84	15	13.5	1.11	0.62-1.83	6	6.1	0.98	0.36-2.13				

Obs = deaths observed; Exp =Deaths expected

<sup>a</sup>Because of changes in disease classification, the earliest follow-up for these cancers was from 1950

<sup>b</sup>Because of changes in disease classification, the earliest follow-up for these cancers was from 1958

<sup>c</sup>The analysis for potential exposure to phenoxy acids above background for 1 year excluded 22 men whose date of first completing a year in potentially exposed jobs was unknown

**Table 4**

Cases of soft tissue sarcoma and sources of diagnostic information

Sub-cohort	Diagnosis	Source(s) of information <sup>a</sup>
A	Dermatofibrosarcoma	CR
A	Chondrosarcoma	CR
C	Leiomyosarcoma of small intestine	CR
D	Soft tissue sarcoma	UC
E	Haemangiosarcoma	CR
E	Liposarcoma	CR
E	Malignant neurilemoma of bone/articular cartilage	CR
E	Chondrosarcoma	CR, UC
E	Spindle cell sarcoma	CR
E	Fibromyxosarcoma	CR, UC
F	Myxosarcoma	CR
F	Leiomyosarcoma peritoneum	CR
F	Round cell liposarcoma	CR
F	Spindle cell sarcoma	CR, UC
F	Sarcoma	CR

<sup>a</sup>CR = cancer registration; UC = underlying cause of death on death certificate

**Table 5**

Associations of soft tissue sarcoma and non-Hodgkin lymphoma/chronic lymphocytic leukaemia with duration and level of potential exposure to phenoxy herbicides above background

Potential exposure to phenoxy acids above background <sup>a</sup>	Number of exposed cases	Number of exposed controls	Odds ratio	95% CI
<b>Soft tissue sarcoma</b>				
None	3	30	Baseline	
<1 year	6	75	0.77	(0.17, 3.50)
1 year	6	45	1.30	(0.30, 5.62)
None	3	27	Baseline	
Low	5	32	0.79	(0.16, 3.89)
High	3	51	0.95	(0.19, 4.88)
<b>Non-Hodgkin lymphoma/chronic lymphocytic leukaemia</b>				
None	16	150	Baseline	
<1 year	28	331	0.77	(0.39, 1.53)
1 year	30	238	1.11	(0.57, 2.18)
None	14	139	Baseline	
Low	17	154	0.67	(0.32, 1.40)
High	28	285	1.22	(0.61, 2.46)

<sup>a</sup>Subjects were classified according to their exposure status 5 years before the date when they or their matched case were first recorded as having the relevant cancer. Analyses by level of potential exposure above background were limited to sub-cohorts E and F.